Treatment with this compound suppressed TCA cycle anaplerosis and proliferation in BPTES-resistant breast cancer cells; moreover, it reduced the tumorigenic potential of MDA-MB-453 cells, supporting a view of GLS2 as a druggable target in luminal-subtype breast cancers [47]. This evidence concerns the gene GLS2 and breast carcinoma.